Creative Biolabs Boosts PROTAC Drug Discovery Comprehensively

Supported by a group of professional scientific team with rich experience accumulated in the field of biotechnology solutions, Creative Biolabs possesses sophisticated techniques and qualified products to support the proteolysis targeting chimeric (PROTAC) based molecular drug discovery.

Shirley, United State - May 18, 2020 /MarketersMedia/ —

Studies indicate that the PROTAC degradation approach has great potentials for treating diseases like cancer, which functions using proteasome-mediated proteolysis via E3 ligase, and the body's degradation system (UPS) to selectively degrade the disease-causing proteins. Such working mechanisms make PROTAC approach more reliable and safe in that there will be lower toxicity but longer and better pharmacodynamics effect, compared with conventional drugs. Creative Biolabs has spent times and energy exploring this method, who is now fully competent to provide technical support and related lab-use molecular substances to push forward associated projects.

The solutions in accordance with PROTAC molecule discovery comprise 5 sections which can be provided in-suite or separately, covering every essential step, to ensure the quality of wanted protac molecules from the initial stage—linker design and linker optimization. As for the clients already with designated protac structure model, Creative Biolabs can help with peptide/compound synthesis that is variable on various platforms, formats, modifications and purity levels, to reach satisfactory results.

Two other options stand as post-discovery steps, one is in vitro evaluation, and the other is in vivo animal test, both assist with verifying the efficacy and safety of PROTAC molecules. The former mainly focuses on the chemical characteristics, while the latter pays more attention to the properties that may affect living organisms, such as toxicity, ADME (absorption, distribution, metabolism, and excretion).

A lot of related standard substances are prepared by Creative Biolabs, for those customers requesting linkers, ligands, ligand-linker conjugate, E3 ligase and target proteins for their projects, to help develop the most effective PROTAC molecules.

"This novel technique is promising to the patients with tricky diseases," said the head scientist of Creative Biolabs, "because it targets undruggable proteins." As a reliable partner in the biotechnology industry, who always keeps up with the technologies, Creative Biolabs is confident to give a push to the pharmaceutical manufacturers and researchers who are working on PROTAC drugs. There are more details about the solutions and products at https://www.creative-biolabs.com/protac/.

Overview
Creative Biolabs, founded in 2004 in the US, is a biotech solution CRO made up of technical research staff that are dedicated to the research and development of drug discovery and engineering. After over 10 years of relentless exploration, its capabilities cover the entire one-stop PROTAC-based drug development process, from early discovery to pre-clinical evaluation and clinical trials. The team have made distinctive achievements in proteolysis targeting chimeric molecule (PROTAC) area, winning a leading position throughout the world. The solutions can fully support PROTAC development projects from ligand identification to biological evaluation.

Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/protac/

Source URL: https://marketersmedia.com/creative-biolabs-boosts-protac-drug-discovery-comprehensively/88957819

Source: MarketersMedia

Release ID: 88957819